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Latent tuberculosis: which test in which situation?
Jean-Pierre Zellweger
Department of ambulatory care and community medicine, University of Lausanne, Switzerland
Detection of latent tuberculosis infection
(LTBI) is a cost-effective procedure in patients at
high risk of developing tuberculosis later and who
could benefit from preventive treatment. The
commonest situation where screening is indicated
is the search for infected contacts of an index case
with pulmonary tuberculosis. As a screening pro-
cedure the current tendency is to replace the
time-honoured tuberculin skin test by one of the
new blood tests measuring the release of inter-
feron gamma by sensitised T lymphocytes after
stimulation by specific peptides from M. tuberculo-
sis. The main advantage of the new tests is the ab-
sence of interference with BCG and non-tubercu-
lous mycobacteria, which confers high specificity
on the test. This allows a more selective choice of
persons for whom preventive treatment is indi-
cated. Some controversial issues remain, such as
sensitivity in children and immunocompromised
subjects, the predictive value of the blood test and
interpretation of possible changes in test results
over time. The technical aspects required for per-
formance of the tests must be considered.
Key words: tuberculosis; latent tuberculosis infec-
tion; tuberculin skin test; interferon-gamma assays;
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Summary
La détection de l’infection tuberculeuse la-
tente (ITBL) est rentable dans toutes les situa-
tions où les personnes infectées courent un risque
élevé de développer ultérieurement une tubercu-
lose et peuvent être bénéficier d’un traitement
préventif. La situation la plus fréquente où un dé-
pistage est indiqué est la recherche de contacts
 infectés dans l’entourage d’un patient atteint de
tuberculose pulmonaire. Comme méthode de dé-
pistage, on tend actuellement à remplacer le tra-
ditionnel test tuberculinique par un des nouveaux
tests sanguins qui mesurent la libération d’Inter-
féron Gamma par les lymphocytes sensibilisés au
contact des antigènes spécifiques de M. tuberculo-
sis. L’avantage principal des nouveaux tests est
l’absence d’interférence avec la vaccination BCG
et les mycobactéries non-tuberculeuses, qui
confèrent ainsi aux tests une spécificité élevée. En
conséquence, le choix des personnes chez les-
quelles un traitement préventif est indiqué est
beaucoup plus sélectif. Il reste cependant des
controverses, telles que l’indication et l’interpré-
tation des tests chez les enfants et les personnes
immunodéprimées, la valeur prédictive des tests
et l’interprétation des modifications possibles de
la réponse au cours du temps. Les impératifs tech-
niques inhérents aux tests doivent être respectés.
Résumé
Introduction
Subjects in contact with patients with smear-
positive pulmonary tuberculosis may be infected if
the index case coughs up and expels mycobacteria
into the air. Infected contacts will then develop a
progressive immune response and some will also
develop the disease after a variable length of time
(from several days to several years depending on
the immunological status). The risk of reactiva-
tion is estimated to be between 5 and 10%
throughout life and depends on several factors,
such as age, sex, size of the tuberculin reaction,
immune status, diabetes, smoking, drug treatment
and nutritional status [1–4]. The risk is higher in
the 2 years following infection and decreases with
time [5].
In all countries the first priority is rapid detec-
tion and treatment of patients with transmissible
forms of tuberculosis. In regions with a high inci-
dence of tuberculosis a search for contacts among
the relatives of smear-positive cases may succeed
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in detecting a large number of secondary cases,
but the search for infected contacts is less of a pri-
ority except among close relatives and small chil-
dren, who may rapidly develop severe forms of
the disease [6]. In countries with a low incidence
of tuberculosis the search for infected contacts is
also considered a priority [7]. Soon after the in-
troduction of antibiotics active against tuberculo-
sis (as early as 1959), trials were conducted which
demonstrated that, if properly prescribed and
taken, preventive treatment reduces the risk of fu-
ture disease [8, 9] and is cost-effective [10]. In the-
ory at least, if applied rigorously to infected indi-
viduals or to whole populations with a high rate of
latent infection, this policy could be successful in
lowering the incidence of tuberculosis in the fu-
ture [11].
Screening for infected individuals may also be
considered in other population groups with a risk
of infection higher than the local average, such as
prison inmates, exposed health-care workers or
immigrants from high-incidence countries or re-
gions. 
As individuals with latent tuberculosis are by
definition healthy and do not present radiological
abnormalities (except, in some cases, a scar from
an earlier primary infection), screening must rely
on immunological markers of infection. For
nearly a century screening relied on the tuber-
culin skin test (TST) but the recent introduction
of T-cell interferon gamma release assays
(TIGRA) has changed the approach to screening
and the indications for preventive treatment [12–
15]. 
The blood tests measure the release of inter-
feron gamma by T lymphocytes after stimulation
with antigens from M. tuberculosis, like the tuber-
culin skin test, but the antigens used are specific
peptides from M. tbc instead of a mixture of anti-
gens, most of which are common to all mycobac-
teria, including M. bovis BCG [16]. The antigens
used in commercial forms of the tests are encoded
in the region of difference (RD1) of the M. tuber-
culosis genome, which is deleted in all M. bovis
BCG strains and absent in the vast majority of
non-tuberculous mycobacteria. 
Compared with the tuberculin skin tests, the
TIGRAs have several characteristics that make
them appear better adapted to screening for la-
tent infection: they are much more specific than
TST because they are not influenced by prior
vaccination with BCG and by contact with most
non-tuberculous mycobacteria (the exception
being M. kansasii, M. szulgai and M. marinum)
[16–18] and they can be repeated without any
booster effect.
In clinical practice TIGRAs, like TST, are es-
sentially used to diagnose latent tuberculous in-
fections (LTBI). The problem is that there is no
gold standard for the diagnosis of LTBI (and
there cannot be such a standard). Most investiga-
tors, however, agree that positive TIGRAs would
occur almost exclusively in subjects who have en-
countered M. tuberculosis, ie subjects who actu-
ally have either LTBI or active tuberculosis. The
consensus is therefore that positive TIGRAs
should never be considered false positive, al-
though the cutoffs for positivity of the commer-
cial tests may need to be adjusted to optimise
their accuracy [19]. As regards sensitivity, on the
other hand, data from TIGRAs obtained in pa-
tients with active tuberculosis can be used as a
surrogate for LTBI because a gold standard for
active tuberculosis does exist (positive culture for
M. tuberculosis together with a compatible clinical
situation). Here it appears that there are some
false negative TIGRAs, but fewer than false nega-
tive TST [20, 21]. Thus TIGRAs may prove
 positive where TST is negative, particularly in
 situations such as severe viral or drug-induced
immunosuppression [22, 23].
In a study among 590 HIV-positive patients
the test performed satisfactorily in all subjects
with CD4 cell counts over 100 [24]. Among pa-
tients on haemodialysis, and among patients who
were immunocompromised for reasons other
than HIV, the blood test also performed better
than the TST [25, 26]. 
In children the use of TIGRAs has produced
controversial results. In one Australian study a
high rate of indeterminate test results was ob-
served among children exposed to tuberculosis
but not among children with documented tuber-
culosis [27]. In another study conducted in Nige-
ria the blood tests correlated better than the TST
with intensity of exposure [28]. In Gambia, TST
showed high specificity among exposed children
and a good correlation with ESAT-6/CFP-10
Elispot [29]. The reason for these discrepancies is
not clear but may be related to the tuberculin
used, the cutoff considered for positivity or the
background prevalence of infection with non-tu-
berculous mycobacteria. A study performed in
Germany has confirmed that the blood tests allow
a distinction between infection with M. tbc and
with non-tuberculous mycobacteria in children in
a low-prevalence country [30]. Individual obser-
vations suggest that the blood tests may convert
to positive before the TST [31].
In spite of their high specificity, the TIGRAs
do not allow a distinction between latent infection
and disease (the same applies to TST), and hence
their use for the diagnosis of tuberculosis remains
controversial [32–34]. As a potential indicator of
disease the tests are probably useful only in popu-
lations where the prevalence of LTBI is low, as in
children from low-incidence countries [35].
The TIGRAs correlate better than the TST
with the intensity of contact with the index case,
in children [28] and in adults [36–38].
In contrast to the TST, the TIGRAs can be
repeated without any booster effect. The possible
influence of a TST performed before blood sam-
pling is controversial, some studies having
demonstrated no influence [39, 40] while others
observed a possible effect [41].
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As the TIGRAs are more specific than the
TST, the number of contacts with a positive
blood test in a contact investigation is lower than
the number of persons with a positive TST, par-
ticularly if the proportion of BCG-vaccinated in-
dividuals is high [18]. But even in populations
with no prior BCG vaccination the number of in-
dividuals found to be positive is lower, probably
due to the exclusion of false positivity associated
with sensitisation with non-tuberculous mycobac-
teria [19, 42], although a true difference in sensi-
tivity between both tests is also possible. As there
is no gold standard for latent infection (except the
later development of disease), the true sensitivity
of the blood tests cannot yet be assessed. In indi-
viduals where the sensitivity of the TST is low,
the TIGRAs may be positive even if the TST is
negative [22]. The main similarities and differ-
ences between TST and TIGRAs are reported in
table 1.
The degree of positivity of the blood tests
tends to decrease during and after preventive or
curative treatment, but seldom reverts to nega-
tive. This may indicate that the bacterial load and
antigenic stimulation have decreased [43, 44], but
it seems premature to conclude that the TIGRAs
can be used to predict the success or failure of
 antituberculous treatment [45]. An intriguing ob-
servation is the spontaneous reversion to negative
of positive test results among contacts tested re-
peatedly but not treated preventively [46, 47].
This phenomenon is also observed with TST,
though more rarely, and may reflect a decrease in
the amount of circulating antigens from M. tbc
and a consequent decrease in the stimulation of 
T lymphocytes. Whether this indicates that the
mycobacteria have entered a stage of dormancy or
have been eradicated spontaneously remains un-
clear [48]. 
The main interest of the TST is that it allows
a crude but reliable evaluation of the risk of con-
tacts with a positive test result developing tuber-
culosis in the future [1]. Predicting this is more
difficult with the TIGRAs as there are no long-
term follow-up studies comparing the risk of tu-
berculosis in populations with positive or negative
test results [49]. The only study published up to
now concerns a small group of 24 contacts who
did not receive preventive therapy and where the
contacts with a positive interferon-gamma test
had approximately twice the risk of developing
tuberculosis within the next 2 years compared to
subjects with a positive tuberculin skin test [50].
Considering the fact that approximately half of
the positive TST are false positive, at least in pop-
ulations with a high BCG vaccination coverage,
this is not surprising, but confirmation is expected
in large populations. Clearly, the answer to this
question would represent an important advance
in our understanding of the mechanism of latent
tuberculosis infection and its control [51].
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Comparison between TST and TIGRAs 
TST QFT T-SPOT.TB
Influenced by prior BCG vaccination Yes No No
Influenced by non-tuberculous mycobacteria Yes No (with exceptions) No (with exceptions)
Booster effect if repeated Possible No No
False positive results Possible No evidence No evidence
False negative results Possible Possible Possible
Correlation with exposure intensity Partial Yes Yes
Antigens used PPD RT23 ESAT-6, CFP-10 ESAT-6, CFP-10  
Technique In vivo skin test ELISA ELISPOT
Results given in mm of induration IFN-g units Spot-forming units 
Table 1
Main similarities and
differences between
tuberculin skin tests
(TST) and T-cell Inter-
feron-Gamma Assays
(QuantiFERON-TB
Gold = QFT and 
T-SPOT.TB)
Indeterminate test results
Although the test results are usually given as
positive or negative, some of them cannot be in-
terpreted and must be considered indeterminate.
The most common reason for such results is the
fact that the positive mitogen control fails to
react, indicating the absence of stimulable lym-
phocytes. This may be due to pre-analytic errors
(freezing of the blood sample during transporta-
tion) or real absence of living lymphocytes. An in-
determinate result may be an indication of an im-
mune defect and should arouse clinical suspicion.
Some factors, such as very young or very old age,
immune deficiencies and use of oral steroids, may
be associated with a higher rate of indeterminate
results [52, 53]. Indeterminate test results should
not be confused with false negative results which
may be observed in some rare patients with active
tuberculosis. 
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Two commercial tests are currently available
on the European market, the QuantiFERON-
TB Gold (and its modified version QuantiF-
ERON-TB in Tube), relying on Elisa technology,
and the T-SPOT-TB test, relying on Elispot tech-
nology. They are more costly than tuberculin skin
tests. In Switzerland both commercial tests are in-
cluded in the official List of Analyses and are re-
funded by health insurance. 
In Elisa technology the concentration of inter-
feron gamma released by lymphocytes after incu-
bation with specific M. tbc antigens is measured di-
rectly in the whole blood. In Elispot technology the
number of lymphocytes releasing interferon gamma
is counted visually after standardisation of the
number of lymphocytes in each incubation well. 
Both tests must be performed in laboratories
with adequate equipment and trained staff, and
the pre-analytic requirements must be carefully
observed, particularly the delay between sampling
and analysis (not more than 8 hours) and the need
to transport the samples at room temperature
(freezing or exposure to cold may inhibit the lym-
phocytes) [53].
Both commercial tests rely on a similar prin-
ciple but differ in their operational characteristics.
In comparative studies they appear to give similar
results among healthy adults, but they may differ
in children and immunocompromised patients
and the results may be discordant. A detailed
comparison of the operational characteristics and
performance of the tests is outside the scope of
this paper and has been addressed in several pub-
lications [22, 55–57].
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Technical aspects
Indications
Screening for LTBI is not an end in itself but
should have therapeutic implications and con-
tribute to evaluation of the risk of developing
 tuberculosis. The main indications for screening
for tuberculosis infection are:
1. Screening for latent tuberculosis infection
(LTBI) among TB contacts.
2. Screening for LTBI before immunosuppres-
sive therapy (recommended) or in immuno-
suppressed patients (debatable).
3. Regular screening among exposed persons
(health-care workers). 
4. Screening of immigrants from high incidence
countries (controversial).
Screening for LTBI among contacts
Considering the high specificity of the blood
tests, two strategies for screening for latent tuber-
culosis infection may be considered: one strategy
proposes to replace the tuberculin skin test en-
tirely by the TIGRAs, at any rate in immunocom-
petent adults, assuming that the sensitivity of both
tests is similar [58, 59]. The advantage of this
strategy is that one single test is needed and there-
fore one single visit for screening. The disadvan-
tage is an increase in overall costs, as the vast ma-
jority of tests will be negative. Another strategy
proposes to perform a tuberculin skin test first, in
order to exclude all contacts who are not infected,
and then to test only the contacts with a positive
TST to separate the true positives from the false
positives. This strategy is less costly [60], but in-
volves two visits (one to perform the TST and one
to read the test and perform the blood test if 
the TST is positive) [61, 62]. Moreover, it requires
the health care staff to be still able to perform 
and correctly read the TST. In population groups
where the probability of immunosuppression is
high or the risk of not presenting for the reading
of the TST is high, immediate performance of the
blood test may be preferable. On the other hand,
according to a model developed by a Canadian
group, in populations with a low prevalence of
 latent TB infection or a strong likelihood of false-
positive TST due to prior BCG vaccination,
 sequential testing (TST with confirmation of pos-
itive test results by TIGRA) may be more cost-
effective [13]. The same model concludes that in
population groups where the prevalence of true
positive TST is high (as in non-vaccinated chil-
dren), the sequential strategy is less cost-effective
than a strategy of single testing.
In healthy children not vaccinated with BCG,
and living in regions where the prevalence of in-
fections with non-tuberculous mycobacteria is
low, the TST still appears to be a satisfactory
screening test since it correlates fairly well with
the future risk of tuberculosis [4, 63, 64]. Also,
blood sampling in small children may fail in a
large proportion of cases [27]. 
Screening before immunosuppressive therapy 
Immunosuppressive therapy, particularly with
anti-TNF, may increase the risk of reactivating
 tuberculosis in patients with latent tuberculosis
infection [65–67]. Screening for LTBI before the
introduction of immunosuppressive therapy and
adequate preventive treatment is therefore justi-
fied. Since the TST may frequently be negative in
patients already receiving drugs with immunosup-
pressive properties, the use of TIGRAs for screen-
ing is currently recommended [59].
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Screening among exposed health-care 
workers 
Health-care workers (HCW) may be exposed
to tuberculosis more frequently than the local
population, particularly in settings where tuber-
culosis is frequent among hospitalised patients
[68] or if there are undiagnosed cases of tubercu-
losis in the hospital [69]. Hence regular monitor-
ing of exposed staff is frequently recommended,
but the use of TST is controversial because a
large proportion of workers have received prior
BCG vaccination and may present a false-positive
reaction [70]. The use of a more specific screening
method, avoiding the influence of BCG vaccina-
tion and the possible booster effect observed in
serial testing with TST, is therefore welcome [71].
Serial testing of HCW with TIGRAs has been
performed but the results may be confused by the
fact that some HCW appear to revert after an ap-
parent conversion, and thus the indications for
preventive therapy may not be clear [72]. 
Screening immigrants from countries 
with a high incidence of tuberculosis
The use of TIGRAs for the screening of large
population groups with a high rate of infection,
such as migrants from countries with a high inci-
dence of tuberculosis, has been considered but is
not performed on a large scale. A recent analysis
has concluded that such a screening procedure is
cost-effective only in groups with a high risk of
disease and in confirming a positive TST with a
blood test [13].
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Conclusions
a) The specificity of the blood tests narrows the
indications for preventive therapy [73]. No
preventive chemotherapy should therefore be
prescribed without confirmation of infection
by a blood test, except in children. This strat-
egy reduces the number of persons needed to
treat to avoid a future case of tuberculosis
from 50 (using TST as a definition of infec-
tion) to 18 [74].
b) Due to technical constraints, the use of
TIGRAs is currently restricted to the situa-
tions where they offer better specificity and
cost-effectiveness than tuberculin skin tests.
c) There are still many open questions regarding
the operational characteristics of the new
TIGRA tests. Clarification of their predictive
value and use in specific population groups
(children, immunosuppressed patients) and
changes in the performance, procedures or
cost of the tests may enlarge their indication
in the future.
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